{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-009397","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.239262+00:00","generated_at":"2026-06-06T14:31:56.722129+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"ARCA biopharma grants options to 7 non-employee directors; stockholders re-elect two directors at annual meeting","bullets":["Board granted options to purchase 6,000 shares each to 7 non-employee directors at $1.64 per share, vesting monthly over 12 months.","Stockholders re-elected Michael Bristow (6,952,545 for) and Robert Conway (6,758,409 for) as directors for three-year terms.","Ratified KPMG LLP as independent auditor for FY2023 with 10,286,650 for, 263,929 against, 68,141 abstain.","Advisory say-on-pay resolution approved: 6,548,473 for, 1,472,454 against, 19,941 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-009397","json":"https://secwatch.observer/filing/0000950170-24-009397.json","markdown":"https://secwatch.observer/filing/0000950170-24-009397.md","text":"https://secwatch.observer/filing/0000950170-24-009397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/abio-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:31:56.722129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dd3fec05ee6c2755220b934f7ebff1e9034a235","claim":"Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2024-01-30 meeting.","evidence_excerpt":"Nominee For Withheld Broker Non-Votes Dr. Michael R. Bristow 6,952,545 1,088,323 2,577,852 Mr. Robert E. Conway 6,758,409 1,282,459 2,577,852","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-30"}],"fact_type":"shareholder_vote"},{"claim_id":"8d79505b7497c5936397f5ac3345bd1dda25fd9e","claim":"Oruka Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-30 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 6,548,473 1,472,454 19,941 2,577,852","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-30"}],"fact_type":"shareholder_vote"},{"claim_id":"e18b13f0c0e4f063cb1692ca6db02e260425a736","claim":"Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2024-01-30 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 10,286,650 263,929 68,141 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}